Stock GANX GAIN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
2.5 USD +1.63% Intraday chart for Gain Therapeutics, Inc. +5.04% -23.43%
May. 14 Gain Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
GL
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
AQ
Gain Therapeutics Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease
AQ
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
GL
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
GL
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
GL
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
GL
Gain Therapeutics to Present at Public Ventures Discovery Day
GL
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
GL
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
GL
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
AQ
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
AQ
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
GL
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
GL
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
AQ
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
GL
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
GL
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
AQ
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
GL
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GANX Stock
  4. News Gain Therapeutics, Inc.
  5. Press Releases